Bulk Drug Import Quality Reports May Be Required From U.S. Firms
This article was originally published in The Tan Sheet
Executive Summary
Pharmaceutical manufacturers may be required to notify FDA when they receive bulk drugs of poor quality, FDA Associate Commissioner for Regulatory Affairs Dennis Baker told a recent House Commerce/ Oversight & Investigations Subcommittee hearing.